China Universal Asset Management »

Taysha Gene Therapies shares owned by China Universal Asset Management

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by China Universal Asset Management from 13F filings

Historical chart of China Universal Asset Management investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by China Universal Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by China Universal Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $103k 36k 2.87
2023-12-31 $38k 22k 1.76
2022-09-30 $999 385 2.60

More positions owned by China Universal Asset Management

Microsoft Corp Common Stock (MSFT)
Nvidia Corp Common Stock (NVDA)
Amazon.com Common Stock (AMZN)
Meta Platforms Inc-class A Common Stock (META)
Vertex Pharmaceuticals Common Stock (VRTX)
Amgen Common Stock (AMGN)
Servicenow Common Stock (NOW)
Gilead Sciences Common Stock (GILD)
Regeneron Pharmaceuticals Common Stock (REGN)
Alphabet Inc-cl A Common Stock (GOOGL)
Adobe Common Stock (ADBE)
Broadcom Common Stock (AVGO)
Visa Inc-class A Shares Common Stock (V)
Apple Common Stock (AAPL)
Uber Technologies Common Stock (UBER)

View all positions for China Universal Asset Management

Top funds holding Taysha Gene Therapies

RA Capital Management
VR Adviser
Vanguard Group
venBio Select Advisor
Baker Bros. Advisors
Artal Group
Millennium Management
Point72 Asset Management
Citadel Advisors
T. Rowe Price Associates
Schonfeld Strategic Advisors
Exome Asset Management
Alphabet
Quantum Private Wealth
Palo Alto Investors

View all funds holding Taysha Gene Therapies